5,6-Dihydroabiraterone

5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013) . Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer) [1][2].

Product Specifications

CAS Number

[219843-75-1]

UNSPSC

12352005

Target

Drug Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/5-6-dihydroabiraterone.html

Solubility

10 mM in DMSO

Smiles

C[C@@]12C(C3=CC=CN=C3)=CC[C@@]1([H])[C@]4([H])CC[C@@]5([H])C[C@@H](O)CC[C@]5(C)[C@@]4([H])CC2

Molecular Formula

C24H33NO

Molecular Weight

351.52

References & Citations

[1]Alyamani M, et al. Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column. J Steroid Biochem Mol Biol. 2017 Sep;172:231-239.|[2]Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26 (28) :4563-71.